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2012. The aim of this study is to understand which of the validation methods recom-
mended in health economics and financial guidelines are practically used across 
different disease areas and business fields. Methods: For this study we reviewed 
guidelines, economic models for diabetes, cardiovascular diseases, and cancers, as 
well as risk-prediction models. The identified validation methods were collected 
and categorized into three groups: face validity, internal verification, and cross 
validity. Results: Twenty-two (22) economic models, 8 risk prediction models, 5 
financial and 7 health economics guidelines were identified. In the guidelines we 
found 3, 14 and 5 methods within the face validity, internal verification, and external 
validity categories respectively. Almost three quarters of the 22 methods identi-
fied were also described in the ISPOR guideline on model validation and the other 
guidelines described 5 to 15 methods. External validation was done for 14 out of the 
22 economic models reviewed in which (part of) the model results were compared 
against other clinical/epidemiology studies (14 models) or other validated models 
(10 models). Internal verification was mainly done through comparison against the 
trials that the models were built on (10 models). Out of the remaining 13 internal 
verification methods only 3 were performed for the economic models. Face valida-
tion was only performed for 3 economic models. ConClusions: This study found 
that there is a substantial gap between the validation steps recommended and those 
actually performed. Hence a more consistent and pragmatic approach needs to be 
taken to validate economic models. In addition, the validation methods performed 
need to be consistently reported.
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AnAlysis of HeAltH CARe Costs in eldeRly PAtients witH MultiPle 
CHRoniC Conditions using A finite MixtuRe of geneRAlized lineAR 
Models
Eckardt M., Brettschneider C., van den Bussche H., König H.H.
University Medical Center Hamburg, Hamburg, Germany
objeCtives: Multimorbid individuals consume a disproportionally large share 
of health care resources. Usually standard (1-component) regression techniques 
are applied to analyse costs in samples of patients with multiple chronic condi-
tions. However, the patient specific number and combination of co-occurring single 
diseases results in inhomogeneous data leading to biased estimates when using 
traditional regression techniques. In this study we analyse health care costs in a 
sample of patients suffering from multimorbidity using a more elaborate approach 
to address this heterogeneity. Methods: We used a subsample of N= 1050 patients 
from a multicentre prospective cohort study of multimorbid primary care patients 
aged 65 to 85 years in Germany who completed a questionnaire on health care utili-
zation covering a 6-month-period. We applied a finite mixture of generalized linear 
models, which belongs to the group of statistical learning algorithms, in order to 
control for unobserved heterogeneity of patient level health care costs focussing on 
the identification of multimorbidity patterns. Results: We detected four different 
groups of patients with regard to total costs. The effect of the presence of an addi-
tional disease on costs differs between these groups. Two diametrically opposed cost 
trends were detected with respect to the number of co-occurring diseases. While in 
one group containing hypertension, joint arthrosis, diabetes, gout, anxiety and lower 
limb varicosis cost increased with the number of co-occurring diseases, in a sec-
ond group including severe hearing loss, asthma/COPD, osteoporosis, neuropathies, 
Parkinson’s disease and chronic ischemic heart disease cost decreased. Diversities 
between groups were also found in the results indicated by diametrically opposed 
influence of single diseases. ConClusions: Our results indicate existing unob-
served heterogeneity in costs among patients suffering from multimorbidity with 
different combinations of single diseases which would remain unconsidered using 
standard regression techniques. Especially different costs trends were detected with 
regard to the number and nature of co-existing diseases.
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‘ReAl-woRld’ MAnAgeMent of tubeRous sCleRosis CoMPlex (tsC) in tHe 
united kingdoM
Demuth D.1, Nasuti P.1, Richards C.1, Gray L.2, Price L.2, Magestro M.3
1IMS Health, London, UK, 2Novartis Pharmaceuticals UK Limited, Frimley, UK, 3Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA
objeCtives: TSC is a multi-system genetic disorder associated with benign lesions 
throughout the body, neurological manifestations, and impaired cognition. As many 
as 8000 people in the UK may have TSC; many cases likely go undiagnosed. Long-
term morbidity and treatment burden associated with TSC are significant, suggest-
ing substantial economic burden. This preliminary study assessed presentation 
patterns of select TSC manifestations in CPRD. Methods: TSC patients were retro-
spectively identified in CPRD (Read: PK5.00) and linked Hospital Episodes Statistics 
(HES; ICD-10: Q85.1) databases. CPRD includes over 5 million active patients from UK 
primary care practices (~8% coverage). A total of 55% of practices (375) are linked to 
HES, allowing events in secondary care to be analysed (e.g. hospitalisations, proce-
dures). Patients not linked to HES were excluded. Available history was extracted for 
each patient; descriptive statistics for select TSC-related diagnoses and procedures 
are presented. All ages reported below are median values. Results: A total of 244 
patients (49% male) with a TSC diagnosis were identified; age at diagnosis was 8 
years, with 70% under 18 years. Patient data history was 20 years; 3 and 11 years 
pre/post initial TSC diagnosis. By age 4, 72% had a record of epilepsy; by 16 years, 
9% had a record of subependymal giant-cell astrocytoma (SEGA); by 18 years, 1% 
had obstructive hydrocephalus; by 43 years, 4% had renal angiomyolipoma (AML) 
[median age at initial recorded diagnosis]. ConClusions: Preliminary analyses 
affirm the utility of CPRD in a real-world study of TSC, and the many emergent TSC-
related manifestations, in a longitudinal fashion. Data are suggestive of evolving 
diagnostic and treatment patterns (30% adults) and may highlight a need for better 
coordination of adult care. Relatively low prevalence of AML was unexpected and 
sents almost 3.4% of the country’s GDP (2010). In terms of employment 23.000 are 
directly employed in the sector, while the total benefit for the Greek economy (both 
direct and indirect) is estimated to approximately 132.000 jobs. Finally, the industry 
accounts for nearly € 400 million tax revenue, half of which affects the economy 
directly. ConClusions: Taking these effects in consideration it stems that for every 
€ 1 of Value added in the production / distribution of the pharmaceutical sector some 
€ 2.6 of Value added is created as an indirect effect and € 5.3 as an induced effect. 
Additionally every job position in the sector in the pharmaceutical (production / 
distribution) sector supports 2.5 jobs due to indirect effects and almost 6 jobs in the 
economy. Finally, for every € 1 in tax revenue provided by the sector, an additional 
€ 1.6 is generated though indirect effect and a total of € 2.2 if the induced effect is 
taken into consideration.
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An AssessMent of tHe use of utility dAtA in long-teRM Cost-
effeCtiveness Models of liPid loweRing tHeRAPies
Kuan R.K.1, Wang A.1, Cong Z.2, Zolfaghari S.1, Gandra S.R.2, Nordyke R.1
1PriceSpective LLC, El Segundo, CA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA
objeCtives: To determine through a literature review how economic evaluations 
incorporate utility data into models when estimating long-term cost-effectiveness 
of lipid lowering therapies in primary and/or secondary cardiovascular disease 
(CVD) prevention. Methods: We used MEDLINE to identify published articles 
reporting cost-effectiveness models. Inclusion criteria included: English language 
articles published from 2000-2013, studies in adults ≥ 18 years old, studies assess-
ing statins or ezetimibe for primary and/or secondary CVD prevention, and studies 
in the US, Canada, UK, Spain, Germany, Australia, Sweden, France, and Italy. Two 
researchers independently identified articles and disagreements were resolved by 
consensus. Results: Sixty-one studies fulfilled the inclusion criteria. Forty-eight 
studies assessed the long-term cost-effectiveness (≥ 10 years) of lipid-lowering ther-
apy— 20 studies were in primary CVD prevention, 19 were in secondary prevention, 
and 9 were in both primary and secondary prevention. 36/48 studies incorporated 
utility parameters into their models. 23/36 models differentiated short-term ver-
sus long-term utility impact of cardiovascular events. Eleven models were able 
to differentiate between short-term and long-term utilities through model struc-
ture, where separate health states were created for events versus post-events (e.g., 
stroke versus post-stroke), and utility values could be assigned to these health states 
accordingly. Twelve models were able to differentiate short-term versus long-term 
utilities by changing the model inputs, where different utility values were applied 
to a health state according to length of time after the event (e.g., event year versus 
subsequent years for a health state, or < 6 months versus > 6 months from time of 
event). Eleven models accounted for the occurrence of multiple events by applying 
disutilities or combining utilities multiplicatively for patients experiencing ≥ 1 event 
over time. ConClusions: Around two-thirds of the published long-term models 
differentiated short-term versus long-term utility impacts of cardiovascular events 
through model structure or utility inputs, which should be incorporated into future 
models on this topic.
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objeCtives: To build an Excel calculator, taking demographic and clinical charac-
teristics of rheumatoid arthritis (RA) patients in Turkey, and estimate the annual 
health care costs. Methods: 2009-2011 data from MEDULA, the Turkish national 
health insurance database, was used for the study. RA patients (ages 18-99) were 
identified for the identification period (June 1, 2010 - December 31, 2010) using 
International Classification of Disease Tenth Revision Clinical Modification (ICD-
10-CM) codes. Patients were grouped as prevalent and incident cases and required 
to have two RA diagnoses at least 60 days apart. In order to estimate risk-adjusted 
total annual costs for prevalent and incident cases, generalized linear models 
(GLMs) were used. Patients’ demographic and clinical characteristics were factors 
to determine the expected annual cost value, with coefficients of the charac-
teristics built in the Excel calculator. A marginal effects table was created after 
GLM estimation by using such calculation. Results: A total of 2,613 patients 
met all inclusion criteria, of which 693 were incident and 1,920 prevalent cases. 
Patients’ demographic and clinical characteristics were entered into the Excel 
calculator. Risk-adjusted annual total costs were calculated at € 2,021 for prevalent 
cases and € 1,818 for incident cases. The most expensive contributor to annual 
expenditures was prior biologic use for both groups. Prevalent patients who were 
prescribed disease-modifying anti-rheumatic drugs (DMARDs) in the baseline 
period incurred € 5,898 more costs than those who were not. For incident cases, 
male patients incurred lower costs (€ 1,818 - € 708 = € 1,110), whereas respiratory 
comorbid conditions increased the total expected health care cost of incident RA 
patients by € 916 (€ 1,818 + € 916 = € 2,734). ConClusions: In outcomes research, an 
Excel calculator serves as an important tool to estimate and compare RA-related 
health care costs.
PRM38
unCoveRing tHe gAP between Model vAlidAtion ReCoMMendAtions 
And PRACtiCe
Kleintjens J., Akpo H.
Deloitte, Diegem, Belgium
objeCtives: Health technology agencies and payers rely on economic models to 
evaluate the value of new treatments. It is therefore critical to ensure the scientific 
credibility of these models through validation, which is also required by NICE since 
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visit combined with extended treatment (starting 0–30 days after outpatient visit) 
with ≥ 1 of the following: a further course of intravenous corticosteroids > 7 days 
after the first course; a course of oral corticosteroids > 7 days after the intravenous 
course; intravenous immunoglobulins or plasma exchange. Algorithms for identify-
ing atypical relapses were also developed. ConClusions: General and outpatient 
ARRs are consistent between the two distinct claims databases and are similar to 
those reported in the literature. Differences in inpatient ARRs may indicate differ-
ences between clinical practices in the two systems. Further investigation in the 
real-world setting is required.
PRM44
CoMPARison of MetHods to identify stAge iiib oR iv MetAstAtiC lung 
CAnCeR PAtients fRoM eleCtRoniC MediCAl ReCoRds
Stafkey-Mailey D., Landsman-Blumberg P., Farrelly E., Eaddy M.
Xcenda, Palm Harbor, FL, USA
objeCtives: Increased use of electronic medical records (EMR) has necessitated 
efficient ways to identify patients with certain clinical characteristics. This study 
compared use of standard fields and standard language recognition of progress 
notes to identify patients with metastatic lung cancer within an oncology-specific 
EMR. Methods: Lung cancer patients (ICD-9-CM: 162.2 - 162.9) with second line 
erlotinib treatment were identified from a proprietary EMR. Method 1 identified 
metastatic disease using standard data fields for diagnoses (196.x – 198.x) and/
or stage (3B/IIIB or 4/IV); Method 2 utilized keyword searches for indications of 
metastases or stage within progress notes. Chart reviews were used to confirm 
advanced disease. Positive and negative predictive values (PPV and NPV) were then 
compared across methods. Results: A total of 740 patients were identified with 
suspected metastatic disease; 60.1% (n= 448) using Method 1. Of the remaining 292 
patients, 282 (96.5%) were identified by metastases and 117 (40.1%) by stage key-
words (Method 2). Overall, 671 (86.6%) were confirmed “metastatic” with chart review 
and 5 patients excluded for evidence of other cancers. Overall, PPV was 100% and 
NPV 6.3%. Of those identified as metastatic using the standard fields, the PPV for 
metastases and stage were 65.5% and 66.3% respectively and 99.3% combined. The 
PPV and NPV among the 287 patients identified only by keyword searches, was 
98.2% and 8.7% respectively for metastases and 49.3% and 89.9% respectively for 
stage. ConClusions: Utilization of standard EMR fields for diagnosis and disease 
stage, when used together, resulted in identification of large numbers of confirmed 
metastatic lung cancer patients. However, for those patients requiring text searches 
for metastases and stage, neither separately nor in combination, could adequately 
identify metastatic disease patients. Further standardization of EMRs and consistent 
entry within oncology practices could reduce the need for labor-intensive, costly 
human chart review in real-world oncology research.
PRM45
AssessMent of A CAnAdiAn PRiMARy CARe eleCtRoniC MediCAl ReCoRd 
dAtAbAse foR use in obseRvAtionAl studies
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objeCtives: Observational data derived from clinical practice is becoming increas-
ingly important to answer questions that cannot be addressed by RCTs. Although 
there are a number of administrative databases in Canada, access to more com-
prehensive, longitudinal clinical data such as smoking status, body weight and 
laboratory values in the primary care setting is limited. The objective of this study 
was to evaluate a Primary Care EMR (Electronic Medical Record) system to deter-
mine its feasibility for use in observational studies. Methods: We analyzed de-
identified patient data from primary Health Care Professionals (HCPs) including 
General Practitioners from 2009-2011. Comprehensiveness and completeness of 
each variable by visit were evaluated. First steps were taken to understand how the 
patient population compares to data from published sources. Results: There were 
3,019,954 patient visits observed by 255,274 active patients (≥ 1 visit). The patient vis-
its were entered by 497 HCPs (152 physicians). Data are available for demographics, 
vitals, smoking status, laboratory values, prescriptions, medical history, diagnosis 
(ICD-9), short term absences and referrals. Completeness of each variable by visit 
ranged from 26% for pulse to 100% for age, sex, lab results and referrals. Initial 
assessment revealed that 85.6% of written prescriptions and 88% of diagnoses were 
recorded using structured fields. The median age of patients in the EMR was 37.2 
years compared to 39.9 years reported by Statistics Canada (July 2011). Younger 
age groups were overrepresented, with the largest difference found in those 20-29 
years; no difference was observed for sex. ConClusions: The status of electronic 
primary care health records in Canada is still in its infancy. The research suggests 
this is a valuable new addition to support observational studies in Canada. Disease 
specific validation studies will be required prior to further analysis. Further research 
is being undertaken to review quality measures.
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evAluAtion of disseMinAtion of bRAziliAn netwoRk foR HeAltH 
teCHnology AssessMent (RebRAts)
Gonçalves L.1, Souza K.M.2, Elias F.T.S.3
1Brazilian Ministry of Health, Brasília-DF, Brazil, 2Brazilian Ministry of Health, Brasília, Brazil, 
3Oswaldo Cruz Foundation MoH, Brasília, Brazil
objeCtives: The Brazilian Network for Health Technology Assessment (REBRATS) 
is composed of universities, hospitals and managing institutions who have among 
their goals the objective to elaborate and disseminate HTA information. The net-
work’s website and database are found at the http://www.saude.gov.br/rebrats and 
are tools to disseminate the policies and methodological guidelines of the network’s 
institutional organization and the studies produced by its members. To evaluate 
the degree of the network’s dissemination on national and international levels by 
analyzing the level of access and the rate of return from site users. Methods: To 
analyze the number of visits to the REBRATS site registered through the Google 
Analytics monitoring and data extraction tool, with the intention of identifying 
warrants further investigation. Robust analyses are planned to comprehensively 
describe the clinical and economic burden of TSC in the UK.
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in ClAiMs dAtAbAses: MetHodology And CHAllenges
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objeCtives: To explore whether multiple sclerosis (MS) incident cohorts can be 
identified in claims databases. Methods: We used several approaches to try 
and identify MS incident cohorts in the US Department of Defense (DOD) and 
MarketScan® databases, based on diagnostic and treatment history. Patients were 
first identified with 1 year of no MS claims or treatment before their first MS 
claim. Sensitivity analyses identified patients with 1–4 years of no MS claims or 
treatment before their first MS claim. Results: In patients with a 1-year baseline 
history with no MS claims or treatment, age and baseline characteristics were 
similar to all MS patients. The mean age at index date (second MS claim) was ~50 
years, in contrast with previous research reporting a mean age at diagnosis of 
25–40 years. Patients aged ≤ 65 years with ≥ 1 MS claim and 4 years of continuous 
baseline enrolment were identified in the DOD (n= 16 444) and MarketScan® (n= 16 
352) databases. With increasing years of baseline history, more patients showed 
evidence of pre-existing MS; the percentage of total patients with no MS claim or 
treatment before the first MS claim decreased from 53.3% (1 year history) to 42.2% 
(4 years history) in the DOD database, and from 23.5% to 15.5% in MarketScan®. 
Despite the decrease in patient numbers, the mean age at index date remained 
high (44–49 years). ConClusions: Results indicate that > 4 years of patient his-
tory is needed to define an incident MS cohort in claims databases. However, the 
4-year claim and treatment-free cohort may be useful for studying treatment 
patterns and their impact on outcomes in recently treatment-naïve MS patients. 
There are substantial challenges in retrospectively identifying incident cohorts 
of MS patients using claims databases and a need for additional, large, real-world 
data sources to study newly diagnosed MS patients.
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objeCtives: Describe the patient characteristics and diabetes markers of type 
2 diabetes (T2D) patients in the newly launched IMS LifeLink Diabetes Cohort in 
France. Monitor the data quality through comparison of measures with a French 
national survey of diabetes patients (ENTRED), the UK National Diabetes Audit (NDA) 
where possible, and the “gold standard” UK Clinical Practice Research Datalink 
(CPRD). Methods: The IMS Diabetes cohort in France supplements patient-level 
data from general practitioners with additional patient data via pop-up technol-
ogy within electronic medical records to facilitate robust epidemiological studies. 
This study compares the T2D patients in the Diabetes Cohort with similar popula-
tions in terms of gender, age, disease duration, and proportion of patients meet-
ing key disease-specific targets (data presented as summary statistics). Results: 
Patient characteristics and diabetes markers were analyzed for T2D patients in the 
Diabetes Cohort (n= 5,142), ENTRED (n= 3,894), UK NDA (n= 1,909,494), and UK CPRD 
(n= 268,618). The mean (SD) age in years was 66 (12.58) in the Diabetes Cohort, 66 
in ENTRED, and 61 (15.35) in CPRD. The mean (SD) time since T2D diagnosis was 
8 (7.7), 11, and 7.7 (6.2) years in the Diabetes Cohort, ENTRED, and CPRD, respec-
tively. Mean (SD) BMI was 30.5 (5.76) in the Diabetes Cohort, 29.5 in ENTRED, and 
30.8 (6.51) in CPRD. HbA1c target level of ≤ 6.5% was met by 32.5%, 34%, 23.5%, 
and 26% of the patients in the Diabetes Cohort, ENTRED, CPRD, and NDA, respec-
tively. ConClusions: Health care systems and data collection methods vary across 
EU countries in general. Data monitoring helps assess data quality and robust-
ness. Based on comparison of patient characteristics and diabetes markers, the 
IMS Diabetes Cohort population does not appear to differ from the ENTRED popula-
tion. Although some differences between the Diabetes Cohort and CPRD data were 
noted, this unique French Diabetes Cohort appears appropriate for epidemiological 
research.
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objeCtives: To develop appropriate algorithms for identifying and classifying 
relapses among patients with multiple sclerosis in claims databases. Methods: 
Algorithms for detecting relapses in claims databases were identified by literature 
searches and refined by neurologists and database experts to identify relapses in 
inpatient and outpatient settings. Definitions were used in the US Department of 
Defense (DOD) and MarketScan® databases to determine annualized relapse rates 
(ARR) occurring after index date (date of second MS medical claim separated by ≥ 30 
days, following ≥ 12 months of continuous enrollment) during the 12-month and all 
available follow-up time. Results: A relapse was defined as an inpatient visit with 
a primary ICD-9-CM diagnosis code 340.xx or both an outpatient visit with any 340.
xx diagnosis code and oral or intravenous corticosteroid use ≤ 7 days of the outpa-
tient visit. ARR estimates in the DOD (N= 15,447) and MarketScan® (N= 35,134) data-
bases were 0.25–0.30 and 0.20–0.27, respectively. For inpatient relapses, estimates 
were 0.04–0.06 in the DOD database and 0.02–0.03 in the MarketScan® database. The 
corresponding estimates for outpatient relapses were 0.20–0.23 and 0.18–0.24. Severe 
relapses required an inpatient visit plus additional evidence of brain or spinal mag-
netic resonance imaging ≤ 7 days before or during hospitalization, or an outpatient 
